Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:41.891Z.
Calculation as of: 2026-10-06T13:30:41.891Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$288.39M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.24M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$279.05M
EV/EBIT Ratio
N/A
TTM Avg
15.89x
3Y Avg
15.15x
5Y Avg
15.15x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $288.39M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $285.57M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $284.24M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.83M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | N/A | 15.89x | 15.15x | 15.15x |
| Abeona Therapeutics Inc. (ABEO)vs › | $291.25M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $276.82M | N/A | 17.57x | 14.15x | 16.75x |
| Standard BioTools Inc. (LAB)vs › | $303.11M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $269.80M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.62M | N/A | 11.31x | 11.31x | 15.93x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
